Premium
Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double‐blind, vehicle‐controlled study in 40 patients
Author(s) -
Schulz P,
Bunselmeyer B,
Bräutigam M,
Luger TA
Publication year - 2007
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2006.01879.x
Subject(s) - pimecrolimus , medicine , eczema area and severity index , dermatology , itching , atopic dermatitis , randomized controlled trial , double blind , tacrolimus , surgery , placebo , alternative medicine , pathology , transplantation
Background and objective Pimecrolimus cream 1% is an effective treatment for atopic eczema. The aim was to investigate its efficacy in asteatotic eczema, a skin disease similar to atopic eczema and its associated dry skin and itching. Methods Single‐centre, randomized, double‐blind, vehicle controlled study in 40 patients with asteatotic eczema. Efficacy was assessed by eczema area and severity index (EASI), investigators global assessment (IGA), patient's self‐assessment, and pruritus severity. Results After 4 weeks of treatment, EASI, the primary efficacy variable, was reduced by 62 ± 7% from baseline in patients on pimecrolimus, compared to 21 ± 14% in patients on vehicle ( P = 0.013). With pimecrolimus there was also a better control of pruritus ( P = 0.042) at week 4 whereas a better control of disease according to self‐assessment could only be observed at weeks 2 ( P = 0.01) and week 3 ( P = 0.08). Conclusion Pimecrolimus cream 1% is effective in patients with asteatotic eczema.